{
    "id": 15761,
    "fullName": "CD274 amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "CD274 amp indicates an increased number of copies of the CD274 gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 29126,
        "geneSymbol": "CD274",
        "terms": [
            "CD274",
            "B7-H",
            "B7H1",
            "hPD-L1",
            "PD-L1",
            "PDCD1L1",
            "PDCD1LG1",
            "PDL1"
        ]
    },
    "variant": "amp",
    "createDate": "12/28/2015",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11593,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with metastatic basal cell carcinoma harboring CD274 amplification and a high mutational burden was sensitive to treatment with Opdivo (nivolumab), demonstrating reduced lesion size after two months of treatment and a nearly complete regression of liver lesions after four months of treatment (PMID: 27942391).",
            "molecularProfile": {
                "id": 16029,
                "profileName": "CD274 amp"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 2513,
                "name": "basal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8932,
                    "pubMedId": 27942391,
                    "title": "Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27942391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14390,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, 66.7% (6/9) of advanced solid tumor patients harboring CD274 amplification demonstrated an objective response when treated with a PD-1/PD-L1 monotherapy (5 patients), a PD-1/PD-L1 therapy combined with an investigational drug (3 patients), or a combination of an anti-PD-1 and anti-CTLA4 therapy (1 patient) (PMID: 29902298).",
            "molecularProfile": {
                "id": 16029,
                "profileName": "CD274 amp"
            },
            "therapy": {
                "id": 5248,
                "therapyName": "unspecified PD-L1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11631,
                    "pubMedId": 29902298,
                    "title": "Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29902298"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14389,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, 66.7% (6/9) of advanced solid tumor patients harboring CD274 amplification demonstrated an objective response when treated with a PD-1/PD-L1 monotherapy (5 patients), a PD-1/PD-L1 therapy combined with an investigational drug (3 patients), or a combination of an anti-PD-1 and anti-CTLA4 therapy (1 patient) (PMID: 29902298).",
            "molecularProfile": {
                "id": 16029,
                "profileName": "CD274 amp"
            },
            "therapy": {
                "id": 3890,
                "therapyName": "unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11631,
                    "pubMedId": 29902298,
                    "title": "Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29902298"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11589,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with cancer of unknown primary harboring CD274 amplification and overexpression, and a hypermutated genome was sensitive to Keytruda (pembrolizumab), demonstrating tumor regression after two months of treatment and a near complete remission after six months of treatment (PMID: 27900363).",
            "molecularProfile": {
                "id": 16029,
                "profileName": "CD274 amp"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 305,
                "name": "carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9654,
                    "pubMedId": 27900363,
                    "title": "Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27900363"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10923,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with SMO antagonist-resistant basal cell carcinoma with high mutational burden and harboring several genomic alterations, including amplification of PD-L1 (CD274) as well as PD-L2 (PDCD1LG2) and JAK2, demonstrated a durable response following treatment with Opdivo (nivolumab) (PMID: 27942391).",
            "molecularProfile": {
                "id": 27860,
                "profileName": "CD274 amp JAK2 amp PDCD1LG2 amp"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 2513,
                "name": "basal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8932,
                    "pubMedId": 27942391,
                    "title": "Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27942391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14391,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a glioblastoma patient harboring amplifications in CD274, PDCD1LG2, JAK2, MET, and MDM2 was sensitive to the combined therapy of Opdivo (nivolumab) and Cometriq (cabozantinib), demonstrating a partial response at four weeks (PMID: 29902298).",
            "molecularProfile": {
                "id": 29995,
                "profileName": "CD274 amp JAK2 amp MDM2 amp MET amp PDCD1LG2 amp"
            },
            "therapy": {
                "id": 2067,
                "therapyName": "Cabozantinib + Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11631,
                    "pubMedId": 29902298,
                    "title": "Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29902298"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 16029,
            "profileName": "CD274 amp",
            "profileTreatmentApproaches": [
                {
                    "id": 7278,
                    "name": "PD-L1/PD-1 antibody",
                    "profileName": "CD274 amp"
                }
            ]
        },
        {
            "id": 27860,
            "profileName": "CD274 amp JAK2 amp PDCD1LG2 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29995,
            "profileName": "CD274 amp JAK2 amp MDM2 amp MET amp PDCD1LG2 amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}